Background. A significant proportion of patients receiving endocardial defibrillation lead systems must accept either high defibrillation thresholds (DFTs) with lower safety margins or lead implantation by thoracotomy. We examined the feasibility of achieving universal application of endocardial leads and lower defibrillation energy requirements by optimizing the lead system location in conjunction with biphasic shocks.
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Background. A significant proportion of patients receiving endocardial defibrillation lead systems must accept either high defibrillation thresholds (DFTs) with lower safety margins or lead implantation by thoracotomy. We examined the feasibility of achieving universal application of endocardial leads and lower defibrillation energy requirements by optimizing the lead system location in conjunction with biphasic shocks.
Methods and Results. Two defibrillation catheter electrodes were positioned in the right ventricle and superior vena cava. Thoracic patch electrodes were placed at three sites (apical, pectoral, and axillary). Fifteen-joule, 10 -J, and 5-J bidirectional simultaneous biphasic shocks were delivered across three different triple electrode configurations (right ventricle, superior vena cava, and patch) after inducing ventricular fibrillation (VF), and DFT was determined. All patients in whom VF was reproducibly inducible (14 patients) could be reproducibly defibrillated at 15 J at one or more patch electrode locations. Fifteen-joule shocks were effective at three thoracic electrode locations in 12 patients and at two electrode locations in 6 patients. The lowest mean single-shock DFI was 8.1±3.8 J. In 4 patients, ventricular flutter was reproducibly induced and reverted at 15 J in all patients. Mean DFT for the axillary location was 83±3.5 J and was significantly lower than apical (12.8±5.6 J, P=.008) and pectoral (11.6+4.1 J, P<.04) patch locations. The probability of success was significantly higher at 10 J with axillary location (78% of patients, P<.03 compared with both other sites) and at 15 J (P<.05 compared with the apical location). Low-energy endocardial defibrillation (s10 J) was feasible in 10 of 14 tested patients at more than 1 thoracic electrode location at 10 J, whereas only 1 of 7 successful patients could be reverted at more than 1 electrode location at 5 J (P<.02).
Conclusions. The use of axillary or pectoral patch lead location can allow endocardial defibrillation with biphasic shocks at energies s15 J in this lead configuration. Virtually universal application of endocardial defibrillation lead systems can be predicted from these data. Reduction in maximum pulse generator output to 525 J using these two thoracic electrode locations with bidirectional shocks can be feasible and maintain an adequate safety margin and permit thoracic pulse generator implantation. Lowering endocardial defibrillation energy <10 J requires increasing specificity of thoracic electrode location. (Circulation. 1993; 88:2655 -2660 Shocks were generated using a Medtronic model 2394 external cardioverter-defibrillator. This device has been described in detail previously.6 It is capable of generating a single monophasic shock or two successive shocks. In the latter mode, the second shock can have the same polarity as the first shock (sequential monophasic shocks) or the reverse polarity to the first shock, ie, a biphasic shock. The only shock waveform used in this study was a biphasic waveform generated in this manner. The two shock pulses were of equal duration and separated by an interpulse interval of 0.2 millisecond. The duration of each pulse was determined by the time taken by the pulse to decay from the leading edge voltage of the pulse to 35% of this value, giving a 65% tilt. The leading edge voltage of the second reversed polarity pulse was also specified. The individual leading edge voltages for the first and second pulses at the stored energy levels corresponding to 15 J, 9.6 J, and 5 J, respectively, were 500/140 V, 400/100 V, and 290/80 V. This voltage range was selected based on prior data on simultaneous biphasic shock efficacy in humans and extent of testing compatible with patient welfare and clinically relevant device refinement. The total capacitance used was 120 liF.
A triple electrode configuration was used and included a right ventricular common electrode paired with electrodes in the superior vena cava/right atrium (pathway 1) or left thorax (pathway 2). Biphasic shocks delivered through this electrode system achieved simultaneous pulsing in dual current pathways. Delivered voltage and current in each pathway were monitored using a three-channel storage oscilloscope. Delivered
Using initial voltage and current data, actual input impedance for each pathway was calculated.
Lead Configurations
Subcutaneous thoracic electrode location was simulated using an adhesive cutaneous patch electrode. We have previously shown excellent concordance of this temporary lead with respect to monophasic shock efficacy and impedance with subcutaneous implantable patch electrodes that are in current clinical practice.2,7 This concordance has been noted for apical, pectoral, and axillary patch locations in our prior studies. The lead locations used in this study were (1) apical: patch center located in the fifth left intercostal space in midclavicular line, (2) axillary: patch center located in the fourth intercostal space in midaxillary line, and (3) pectoral: patch center in the second intercostal space in the midclavicular line. The patch electrode was connected to the anodal terminal of the external cardioverter-defibrillator using a Y-connector.
Study Design
The three electrode locations were tested in a predetermined randomized order using a computer-generated randomization schedule. VF was induced using 60-Hz alternating current through the bipolar intracardiac electrodes. The first defibrillation energy level had an initial leading edge shock voltage of 500 V, with an estimated stored energy level of 15 J. If the first shock was successful, a similar process was repeated for each of the other two randomized lead positions at the same energy level. For an unsuccessful shock, a rescue shock was delivered either through the same electrode system at higher voltage or using a transthoracic defibrillation system. If the 15-J energy level was successful at any of the patch locations, stepwise reduction to the 10-J storage energy level (initial shock leading edge voltage, 400 V; actual calculated stored energy, 9.6 J) was undertaken. The patch location(s) showing efficacy at 15 J were randomly tested at 9.6 J. If the 9.6-J energy level was successful at any patch location, testing of the 5-J energy level (initial shock leading edge voltage, 290 V) was undertaken. The protocol was terminated if all three lead positions were noted to be ineffective for VF reversion at one or more voltage levels or if the patient's clinical status precluded further testing. In the latter instance, only the lowest effective energy was recorded. Alternatively, if success was still present at 5 J, the shock was deemed effective at <5 J, and the lower voltages were not tested for that patch position. Rescue shocks were not used in determining efficacy at a patch location in the 5-to 15-J energy range.
Definitions and Statistical Analysis
The definitions used in this study were 
Defibrillation Testing
The lowest effective energy for VF or ventricular flutter could be elicited in 13 patients at the apex and in all patients at the pectoral or axillary thoracic electrode location. DFT could be obtained or estimated at 20 J at the apical position in 12 patients, axillary position in 12 patients, and pectoral position in 12 patients. The lowest mean DFT for the best patch electrode location in 15 patients in whom it could be obtained was 8.1±3.8 J. The Table shows analyzed in 13 of 18 patients. The mean resistance in the total lead system and in the individual pathways were comparable for all three electrode locations (Fig 3) . Regardless of electrode location, the right atrial-right ventricular pathway had a significantly lower resistance than the thoracic patch-right ventricular path (P<.01). Mean current in the total system and in individual pathways did not differ in the three electrode locations. Delivered shock mean pulse widths for the first shock phase were 6.7+0.8 milliseconds with the apical electrode, 7.0±0.8 milliseconds with the axillary electrode, and 7.1+0.8 milliseconds with the pectoral electrode (P>.2). For the second shock phase, mean pulse width was 6.6±0.9 milliseconds with the apical electrode, 6 .9+0.9 milliseconds with the axillary electrode, and 6.9±0.8 milliseconds with the pectoral electrode.
Defibrillation Reliability
The probability of repeated reliable defibrillation or cardioversion at a particular energy level was also analyzed from these data, eliminating electrode location as a variable. In 12 of the 18 patients in this study, three successive reversions of induced VF or ventricular flutter could be demonstrated at a 15-J or lower energy level. In the 6 remaining patients, two attempts at 15 J were successful. At the 9.6-J level, 4 patients tested demonstrated three consecutive successes. Six patients at the 9.6-J level and 1 patient at the 5-J level also had two successful reversions of VF or ventricular flutter. The remaining 2 patients at the 9.6-J level and 2 patients at the 5-J level were not tested for reproducibility. A 15 J or lower, DFT could be obtained for at least one and often more lead configurations in all patients using single-shock DFT data from each patch location. Twelve patients had successful reversions at 15 J at all three locations, whereas the remaining 6 patients demonstrated successful reversion at two electrode locations. At the 9.6-J level, 4 patients had successful reversion at all three electrode locations, 6 patients at two locations, and 2 patients at only one location. At the 5-J level, 1 patient had successful reversion at two thoracic electrode locations, whereas the remaining 5 patients could only be reverted at one location. Lowenergy endocardial defibrillation (< 10 J) was feasible in 10 of 14 patients tested at more than one thoracic electrode location, whereas only 1 of 7 patients could be reverted at more than one location at 5 J. The likelihood of more than one thoracic electrode location being effective was higher at 9.6 J than at 5 J (P=.013).
Probability of Success Analysis
The percent efficacy for defibrillation and cardioversion for biphasic shocks regardless of patch location is shown in Fig 4. When stratified by patch location in the figure, a significantly greater efficacy at 9.6 J at the axillary location is seen compared with the other two sites. At 15 J, the axillary location remains significantly superior to the apical location. It must be emphasized that individual shock efficacy can vary at each energy level for each thoracic patch location.
Discussion
Widespread clinical experience has now been obtained with endocardial lead systems for ICDs.1-4 The bulk of this experience is with devices with monophasic shock capability. There has been a marked reduction in perioperative mortality with improved total survival during the first 3 years of follow-up.4 Sudden death protection has been maintained as compared with epicardial lead systems. These clinical data have also confirmed several earlier observations.2 These include the need for extensive preoperative or intraoperative lead system testing for lead positioning and satisfactory monophasic DFTs. Despite extensive testing, in a recent multicenter experience, approximately 28% of patients did not meet an implant criterion of three conversions in four attempts at 18 J using monophasic shocks. 4 In addition to limiting universal use of this lead system, this precluded any serious possibility of reducing maximum pulse generator output below 30 J due to lack of a satisfactory safety margin. Early efforts to achieve higher implant rates with nonthoracotomy approaches included use of patch mapping, change in lead polarity, or location.2,3'9 Biphasic shocks have been reported to enhance efficacy of transthoracic defibrillation but have more limited advantages in epicardial defibrillation.10'11 We have recently reported significantly increased efficacy and reduced defibrillation energy requirements with endocardial lead systems with simultaneous biphasic shocks.6 Similar advantages with cardioversion of ventricular flutter and tachycardia were also observed with endocardial leads.7 In this study, we conducted a controlled experiment to determine if the use of two beneficial approaches, ie, simultaneous biphasic shocks and optimal patch electrode location, could address the concerns seen in monophasic ICD system trials with endocardial leads. In addition to high-implant DFTs and inability to implant universally, complications such as infection and lead dislodgment have bedeviled current experience.4 Long procedure times with extensive testing and use of locations such as the coronary sinus, which are prone to lead dislodgment, have contributed to these results. Finally, the long lead tunneling procedure from the thoracic venous entry site(s) to the abdominal generator pocket is an aggravating factor for infection and lead complications.
The results of this study provide an encouraging and pivotal experience to address these issues. The data clearly predict high endocardial defibrillation efficacy at 15 J with biphasic shocks using an axillary or a pectoral electrode location. Defibrillation probability curves indicate that the axillary location is superior at 9.6 J, but pectoral and axillary locations achieve near parity at 15 J. Electrode location becomes more critical at l10 J with only one or two locations permitting this low DFT. Five-joule values for DFT were more likely to have one specific electrode site than 9.6-J values. Furthermore, the DFT of the apical site could actually have been higher, with 20-J estimates used by us in 4 patients being conservative values. While recognizing that the sample size is moderate, these data clearly merit further study in a larger multicenter study. However, earliest series of endocardial defibrillation lead efficacy were of similar size.
A 10-J safety margin would be available in the vast majority of patients with a 25-J maximum output device. This would clearly be helpful in reducing device size and pectoral implant of a smaller unit. Still lower outputs (20 J) may be considered for more than 70% of the patients in this study. Current 30-to 35-J monophasic devices have occasionally been implanted pectorally in obese patients or in a submammary location in women.12,13 Erosion and device migration with large subcutaneous thoracic devices are significant concerns in most patients and would require submuscular implantation. This is a more extensive surgical procedure. A smaller device with lower output would be more suitable for subcutaneous thoracic implant. To achieve a DFT c9.6 J requires a pectoral or an axillary electrode location in most patients. Pectoral implant by eliminating tunneling procedures would clearly reduce the surgical field and procedure and lower the risk of infection. The use of a triple lead system that excludes the coronary sinus or other locations such as the right ventricular outflow tract in this study also has some promise for improving lead dislodgment risk. Atrial and ventricular endocardial leads have been long evaluated for stability and performance and should be less prone to dislodgment than the previously mentioned locations (1% in pacemaker recipients). The 
